Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2026
Summary
In gastroparesis Dopamine (D2) receptor is a major focus of drug developers. There are 17 drugs in the pipeline with 90% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The rising prevalence and more frequent use of newer symptomatic treatments are expected to drive the market. However, the market growth is limited by delayed diagnosis, frequent usage of over-the-counter medicines, and decreased compliance due to side effects associated with gastroparesis therapies.
This reports provides a data-driven overview of the current and future competitive landscape in gastroparesis therapeutics.
Scope
GlobalData’s Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook